Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-30 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
EV/EBITDA
1.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.6
Face value
--
Shares outstanding
2,349,480
CFO
$-285.67 Mln
EBITDA
$-358.34 Mln
Net Profit
$-382.57 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neoleukin Therapeutics (NLTX)
| -65.7 | -74.0 | -77.3 | -59.9 | -75.2 | -40.3 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Neoleukin Therapeutics (NLTX)
| -89.4 | -65.8 | 14.4 | 470.4 | -81.5 | -28.8 | 32.3 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Neoleukin Therapeutics (NLTX)
|
3.5 | 8.2 | 0.0 | -39.4 | -- | -54.6 | -- | 0.4 |
| 0.7 | 16.2 | 0.4 | -60.9 | -3,716.2 | -- | -- | 17.3 | |
| 3.4 | 93.0 | 1.0 | -27.1 | -2,935.3 | -125.1 | -- | 6.0 | |
| 228.7 | 43,154.8 | 2,300.4 | -750.2 | -35.0 | -28.5 | -- | 16.9 |
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to... mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Read more
CEO, Pres, Principal Financial Officer & Director
Dr. Jonathan G. Drachman M.D.
CEO, Pres, Principal Financial Officer & Director
Dr. Jonathan G. Drachman M.D.
Headquarters
Seattle, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Neoleukin Therapeutics (NLTX) is $3.49 (NASDAQ) as of 19-Dec-2023 09:30 EDT. Neoleukin Therapeutics (NLTX) has given a return of -75.23% in the last 3 years.
Since, TTM earnings of Neoleukin Therapeutics (NLTX) is negative, P/E ratio is not available.
The P/B ratio of Neoleukin Therapeutics (NLTX) is 0.44 times as on 21-Dec-2023, a 89 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.50
|
0.30
|
|
2021
|
-4.55
|
1.86
|
|
2020
|
-30.58
|
3.99
|
|
2019
|
-8.72
|
4.28
|
|
2018
|
-1.61
|
0.70
|
The 52-week high and low of Neoleukin Therapeutics (NLTX) are Rs -- and Rs -- as of 02-Apr-2026.
Neoleukin Therapeutics (NLTX) has a market capitalisation of $ 8 Mln as on 21-Dec-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Neoleukin Therapeutics (NLTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-10.47
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.